CA2424000C - Utilisation de bleu de methylene et de composes apparentes pour prevenir une reaction hemodynamique excessive ou en inverser les effets - Google Patents

Utilisation de bleu de methylene et de composes apparentes pour prevenir une reaction hemodynamique excessive ou en inverser les effets Download PDF

Info

Publication number
CA2424000C
CA2424000C CA002424000A CA2424000A CA2424000C CA 2424000 C CA2424000 C CA 2424000C CA 002424000 A CA002424000 A CA 002424000A CA 2424000 A CA2424000 A CA 2424000A CA 2424000 C CA2424000 C CA 2424000C
Authority
CA
Canada
Prior art keywords
nitroglycerin
sildenafil
organic nitrate
inhibits
sildenafil citrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002424000A
Other languages
English (en)
Other versions
CA2424000A1 (fr
Inventor
Martin Juneau
Jean-Francois Tanguay
Denis Brouillette
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Montreal Heart Institute
Original Assignee
Montreal Heart Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002379211A external-priority patent/CA2379211A1/fr
Application filed by Montreal Heart Institute filed Critical Montreal Heart Institute
Priority to CA002424000A priority Critical patent/CA2424000C/fr
Publication of CA2424000A1 publication Critical patent/CA2424000A1/fr
Application granted granted Critical
Publication of CA2424000C publication Critical patent/CA2424000C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002424000A 2002-03-28 2003-03-28 Utilisation de bleu de methylene et de composes apparentes pour prevenir une reaction hemodynamique excessive ou en inverser les effets Expired - Fee Related CA2424000C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002424000A CA2424000C (fr) 2002-03-28 2003-03-28 Utilisation de bleu de methylene et de composes apparentes pour prevenir une reaction hemodynamique excessive ou en inverser les effets

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA002379211A CA2379211A1 (fr) 2002-03-28 2002-03-28 Utilisation du bleu de methylene pour renverser la reaction hemodynamique exageree induite par la combinaison d'un derive nitre et du sildenafil ou d'une molecule de meme classe (inhibiteur de la phosphodiesterase)
CA2,379,211 2002-03-28
CA002424000A CA2424000C (fr) 2002-03-28 2003-03-28 Utilisation de bleu de methylene et de composes apparentes pour prevenir une reaction hemodynamique excessive ou en inverser les effets

Publications (2)

Publication Number Publication Date
CA2424000A1 CA2424000A1 (fr) 2003-09-28
CA2424000C true CA2424000C (fr) 2008-07-08

Family

ID=29216701

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002424000A Expired - Fee Related CA2424000C (fr) 2002-03-28 2003-03-28 Utilisation de bleu de methylene et de composes apparentes pour prevenir une reaction hemodynamique excessive ou en inverser les effets

Country Status (1)

Country Link
CA (1) CA2424000C (fr)

Also Published As

Publication number Publication date
CA2424000A1 (fr) 2003-09-28

Similar Documents

Publication Publication Date Title
Liaudet et al. Nonselective versus selective inhibition of inducible nitric oxide synthase in experimental endotoxic shock
Alican et al. A critical role for nitric oxide in intestinal barrier function and dysfunction
Levy et al. Intravenous milrinone in cardiac surgery
Hosseinian et al. Methylene blue: Magic bullet for vasoplegia?
Wilson et al. Mechanisms and pathology of monocrotaline pulmonary toxicity
Kubes et al. Nitric oxide and intestinal inflammation
Gillies et al. Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease
Kirkebøen et al. The role of nitric oxide in sepsis–an overview
Cepinskas et al. Inflammatory response in microvascular endothelium in sepsis: role of oxidants
Price et al. Myocardial dysfunction in sepsis: mechanisms and therapeutic implications
Wu et al. Ascorbate protects against impaired arteriolar constriction in sepsis by inhibiting inducible nitric oxide synthase expression
AU703540B2 (en) Methods for inducing analgesia or anesthesia and treating or preventing ischemic injury of tissues in general
AU2003215474B2 (en) Use of methylene blue and related compounds to prevent or reverse an exaggerated hemodynamic reaction
Gibaldi What is nitric oxide and why are so many people studying it?
Raja et al. Sildenafil: emerging cardiovascular indications
CA2860473A1 (fr) Therapie combinee destinee au traitement du cancer
Radomski et al. Model for theophylline overdose treatment with oral activated charcoal
Westberg et al. Exogenous nitric oxide prevents endotoxin-induced glomerular thrombosis in rats
Mackenzie et al. Nitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritis
Atkinson The use of N-acetylcysteine in intensive care
Murray et al. Nitric oxide and septic vascular dysfunction
US6281222B1 (en) Compositions and method for treatment of acetaminophen intoxication
Hua et al. Role of nitric oxide in hemorrhagic shock-induced bacterial translocation
Meune et al. Interaction between angiotensin-converting enzyme inhibitors and aspirin: a review
Werns et al. Nitroglycerin inhibits experimental thrombosis and reocclusion after thrombolysis

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140328